logo
ADPT_building
MRD testing can benefit both multiple myeloma patients and providers, not only enabling precise monitoring of disease burden, which can help guide patient management, but also allowing patients to feel informed and empowered in the face of a diagnosis that introduces overwhelming uncertainty into their lives,” said Susan Bobulsky, Senior Vice President, Diagnostics, Adaptive Biotechnologies

New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and HealthTree Foundation, a patient-driven, 501(c)(3) non-profit organization that empowers patients at each step of their disease journey, today announced findings from a new survey of 635 U.S. multiple myeloma patients which revealed important insights about the value of minimal residual disease (MRD) testing from the patient’s perspective

By Adaptive Biotechnologies
Published - Nov 21, 2022, 07:39 AM ET
Last Updated - Aug 01, 2024, 03:52 AM EDT
  • >95% of patients who had an MRD test describe that MRD testing helped inform treatment decisions or brought comfort in their treatment journey
  • 85% of surveyed patients have heard of MRD testing, yet only 47% report having had an MRD test, highlighting an opportunity to expand education to benefit more patients
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024